EMEA Liquid Biopsy Market Insights Report Overview
According to the latest market study by MarkNtel Advisors titled “EMEA Liquid Biopsy Market Size, Share, Trends, Growth, Opportunity Analysis 2023-2028” presents a thorough examination of market drivers, opportunities and challenges.
Utilizing a quantitative approach, it offers precise insights into market size, share, and growth. Crafted by industry experts, the report delves into consumption patterns, geographical analysis, and competitive landscapes. Its objective is to furnish valuable insights for clients seeking to comprehend and leverage market dynamics. With a dual focus on historical achievements and future projections, it furnishes a nuanced understanding of the market terrain.
EMEA Liquid Biopsy Market Overview:
The EMEA Liquid Biopsy Market is projected to grow at a CAGR of around 13.98% during the forecast period, 2023-28.
In case you missed it, we are currently revising our reports. Click on the “request sample report“ button to get the latest research data with forecast for the years 2024 to 2030, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report.
EMEA Liquid Biopsy Market Trend:
Rising Use of ctDNA to Enhance the Accuracy of Liquid Biopsy – Liquid biopsy has the potential to improve the treatment for patients who are diagnosed with cancer. However, researchers are exploring the potential use of ctDNA for early detection & symptoms of tumors in the blood. For instance, GRAIL (Gene recognition and analysis internet link) has developed a multi-cancer blood test-based DNA methylation pattern in ctDNA. This technology enables the identification & treatment of cancer at an earlier stage when the treatment is likely to be more effective & chances of survival are high. In addition, it allows us to shift the drugs that are currently being trailed in the last stage of cancer into the early stages of the disease, helping to build more effective cancer treatment. Thus, liquid biopsy technology coupled with ctDNA analysis is the emerging technology that would certainly augment the revenue growth of the EMEA Liquid Biopsy Market in the coming years.
Competitor Insight: EMEA Liquid Biopsy Market
This report focuses on major market participants like:
- Thermofisher Scientific
- Hoffmann-La Roche Ltd
- Sysmex Corporation
- Qiagen N.V.
- Guardant Health
- Bio Rad
- Neo Genomics
- Epigenomics
- Menarini-Silicon Biosystems
- Agena Bioscience Inc.
- Silicon Biosystems
- Pathway Genomics Corporation
- Others (Myraid Genetics, Illumina Inc.,etc)
Explore Our Comprehensive Study: https://www.marknteladvisors.com/research-library/emea-liquid-biopsy-market.html
Segmentation Summary: EMEA Liquid Biopsy Market
This segmentation analysis outlines prominent sections in the report’s table of contents. Each segment undergoes thorough analysis, including sub-segments, to showcase both current and historical market sizes. The analysis underscores investment opportunities for rapid growth, particularly in the EMEA Liquid Biopsy Market, with notable highlighting on:
-By Sample Type
- Blood
- Urine
- Others (Tissue, saliva, etc.)
Blood Sample-based Testing dominated the EMEA Liquid Biopsy Market during the historical years, as it is highly preferred by cancer patients owing to its least invasive nature & reduced risk of incision into the body. The blood samples can be used to detect various biomarkers like ctDNA, CTC, etc., and also allows for reducing the cost & time for the diagnosis. Further, the collection of blood samples is the most convenient method of diagnosis & has been majorly used for the detection of brain, lung, and breast cancers across the region, as it is one of the most painless methods of cancer detection. In addition to this, it can also detect the recurrence of cancer after treatment & helps in early detection & blood-based tests ongoing research for cancer is expected to drive the market in upcoming years.
-By Product and Services
- Equipment
- Assay Kits
- Services
-By Circulating Biomarker
- Circulating Tumour Cell (CTC)
- Circulating Tumour DNA (ctDNA)
- Cell Free DNA (cfDNA)
- Extracellular Vesicle (EVS)
-By Technology
- Multi gene analysis by Next Generation Sequencing (NGS)
- Single gene analysis by Polymer chase reaction (PCR)
-By Application
- By Cancer Application
- By Non Cancer Application
- By Clinical Application
-By End User
- Hospital and Physician laboratories
- Reference Laboratories
- Academic & Research Centre
EMEA Liquid Biopsy Market Geographical Reach:
- Germany
- The UK
- France
- Italy
- Spain
- Saudi Arabia
- The UAE
- Egypt
- South Africa
- Rest of Europe Middle East & Africa
Get Customized Reports As Per Your Requirements: https://www.marknteladvisors.com/query/request-customization/emea-liquid-biopsy-market.html
Key Questions Addressed:
- Factors Driving Market Growth: Understand the primary drivers propelling the EMEA Liquid Biopsy market forward.
- Access to Reliable Reports: Learn where to access dependable market reports for informed decision-making.
- Growth Projections: Gain insights into anticipated growth projections for the coming years.
- Geographical Hotspots: Identify geographical poised for significant market growth soon.
About Us
MarkNtel Advisors is a leading market research company, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.
Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 14.8 diverse industrial verticals.
Media Representative
Company Name: MarkNtel Advisors
Email: sales@marknteladvisors.com
Phone: + 1 628 895 8081, +91 120 4278433
